Marshall Wace’s Trueblue TBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$962K Buy
+104,545
New +$956K ﹤0.01% 2218
2025
Q2
– Sell
-166,115
Closed -$882K – 3163
2025
Q1
$882K Buy
+166,115
New +$1.13M ﹤0.01% 1840
2024
Q4
– Sell
-62,964
Closed -$497K – 2998
2024
Q3
$497K Sell
62,964
-80,946
-56% -$728K ﹤0.01% 1918
2024
Q2
$1.48M Buy
143,910
+110,495
+331% +$1.2M ﹤0.01% 1509
2024
Q1
$418K Sell
33,415
-5,380
-14% -$69.6K ﹤0.01% 2000
2023
Q4
$595K Buy
+38,795
New +$542K ﹤0.01% 1647
2022
Q4
– Sell
-17,040
Closed -$325K – 3411
2022
Q3
$325K Buy
+17,040
New +$345K ﹤0.01% 2917
2022
Q1
– Sell
-365
Closed -$10K – 4002
2021
Q4
$10K Buy
+365
New +$10.3K ﹤0.01% 3755
2019
Q4
– Sell
-25,123
Closed -$530K – 2046
2019
Q3
$530K Buy
+25,123
New +$519K ﹤0.01% 1093
2017
Q1
– Sell
-63,986
Closed -$1.58M – 715
2016
Q4
$1.58M Buy
+63,986
New +$1.35M 0.01% 684
2014
Q4
– Sell
-63,248
Closed -$1.6M – 959
2014
Q3
$1.6M Buy
+63,248
New +$1.75M 0.02% 482

Other funds holding TBI

Marshall Wace's TBI Position: Q3 2026 in Review

Marshall Wace opened a new position in Trueblue (TBI) in Q3 2026: 104,545 shares worth $962K. The stake represents ﹤0.01% of the portfolio and ranks #2218 among its holdings. This is a return to the name: Marshall Wace previously reported a position in TBI as recently as Q1 2025.

Marshall Wace first reported a position in TBI in Q3 2014 and has held it in 11 quarters since. The position peaked at $1.6M in Q3 2014. 97 funds tracked by Wall St. Rank hold TBI as of Q3 2026.

  • Marshall Wace held 104,545 shares of Trueblue worth $962K as of Q3 2026.
  • Trueblue was a new Marshall Wace position in Q3 2026.
  • Trueblue made up ﹤0.01% of Marshall Wace's portfolio in Q3 2026, its #2218 holding.
  • Marshall Wace first reported a position in Trueblue in Q3 2014 and has held it in 11 quarters since.
  • Marshall Wace's Trueblue position peaked at $1.6M in Q3 2014.
  • 97 funds tracked by Wall St. Rank held Trueblue as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.